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Health economicsBackground: Documenting the distribution of radiotherapy departments and the availability of radiother-
apy equipment in the European countries is an important part of HERO – the ESTRO Health Economics in
Radiation Oncology project. HERO has the overall aim to develop a knowledge base of the provision of
radiotherapy in Europe and build a model for health economic evaluation of radiation treatments at
the European level. The aim of the current report is to describe the distribution of radiotherapy equip-
ment in European countries.
Methods: An 84-item questionnaire was sent out to European countries, principally through their
national societies. The current report includes a detailed analysis of radiotherapy departments and equip-
ment (questionnaire items 26–29), analyzed in relation to the annual number of treatment courses and
the socio-economic status of the countries. The analysis is based on validated responses from 28 of the 40
European countries deﬁned by the European Cancer Observatory (ECO).
Results: A large variation between countries was found for most parameters studied. There were 2192
linear accelerators, 96 dedicated stereotactic machines, and 77 cobalt machines reported in the 27 coun-
tries where this information was available. A total of 12 countries had at least one cobalt machine in use.
There was a median of 0.5 simulator per MV unit (range 0.3–1.5) and 1.4 (range 0.4–4.4) simulators per
department. Of the 874 simulators, a total of 654 (75%) were capable of 3D imaging (CT-scanner or CBCT-
option). The number of MV machines (cobalt, linear accelerators, and dedicated stereotactic machines)
per million inhabitants ranged from 1.4 to 9.5 (median 5.3) and the average number of MV machines
per department from 0.9 to 8.2 (median 2.6). The average number of treatment courses per year per
MV machine varied from 262 to 1061 (median 419). While 69% of MV units were capable of IMRT only
49% were equipped for image guidance (IGRT). There was a clear relation between socio-economic status,
as measured by GNI per capita, and availability of radiotherapy equipment in the countries. In many low
income countries in Southern and Central-Eastern Europe there was very limited access to radiotherapy
and especially to equipment for IMRT or IGRT.
Conclusions: The European average number of MV machines per million inhabitants and per department
is now better in line with QUARTS recommendations from 2005, but the survey also showed a signiﬁcant
heterogeneity in the access to modern radiotherapy equipment in Europe. High income countries espe-
cially in Northern-Western Europe are well-served with radiotherapy resources, other countries are fac-
ing important shortages of both equipment in general and especially machines capable of delivering high
precision conformal treatments (IMRT, IGRT).
 2014 Elsevier Ireland Ltd. Radiotherapy and Oncology 112 (2014) 155–164 This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
156 Radiotherapy equipment in EuropeEvidence-based regimens and novel high precision technology
have reinforced the important role of radiotherapy in contempo-
rary multimodality management of cancer. Current data estimate
that about 50% of all cancer patients would beneﬁt from radiother-
apy during the course of their disease, with many of them requir-
ing several courses of treatment [1,2]. Due to signiﬁcant technical
improvements, it is now possible to cure more patients with fewer
side effects. This requires, however, access to modern equipment,
including intensity modulated radiotherapy (IMRT), image-guided
radiotherapy (IGRT), stereotactic radiotherapy and, most recently,
particle therapy [3–11]. The European situation is highly diverse
with large differences in demographics, cancer incidence and eco-
nomic resources among countries. From the ‘‘Radiation Therapy for
Cancer: Quantiﬁcation of Radiation Therapy Infrastructure and
Stafﬁng Needs’’ (QUARTS) project and more recent analyses, it
has been shown that parts of Europe are well-served in radiother-
apy resources, whereas others are facing important shortages as
well in terms of equipment and infrastructure as of trained person-
nel [12,13].
The ESTRO initiated HERO-project (Health Economics in Radia-
tion Oncology) has the overall aim to develop a knowledge base
and a model for health economic evaluation of radiation treat-
ments at the level of individual European countries [14]. To accom-
plish these objectives, the HERO project addresses availability,
needs, cost and cost-effectiveness of radiotherapy. By providing
an updated and validated description of the European radiotherapy
landscape in collaboration with the national societies, and through
the development of web-based cost and cost-effectiveness models,
ESTRO wants to support the European countries and their national
radiotherapy societies in benchmarking their position in Europe
and computing the cost and cost-effectiveness of radiotherapy in
their speciﬁc economic context.
This ﬁrst part of the HERO program is based on a detailed survey
providing an inventory of European radiotherapy in terms of
resource availability (departments, equipment, and personnel),
guidelines and reimbursement. The data will be presented in three
simultaneous papers. The two other papers address stafﬁng [15]
and guidelines [16], respectively, while the current paper focuses
on the distribution of radiotherapy equipment in European
countries.Materials and methods
A web-based questionnaire consisting of 84 questions relating
to population and cancer incidence, radiotherapy activity and
resources, guidelines and reimbursement was developed and dis-
tributed to national scientiﬁc and professional radiotherapy socie-
ties. The full details of the data collected, the methodological
considerations and the practical decisions regarding the data set
used for the entire analysis, are described in the Supplementary
Documentation.
The current report includes a detailed analysis of radiotherapy
departments and equipment (questionnaire items 26–29) in the
countries deﬁned by the European Cancer Observatory (ECO), ana-
lyzed in relation to the annual number of patients treated in the
same countries. Among the 34 ECO countries responding to the
questionnaire, 28 countries could be included in the analysis of
equipment (Table 1): 24 countries with complete datasets, and 4
countries (Belarus, Germany, Italy and United Kingdom) with par-
tial data. The remaining 12 ECO countries (Romania, Slovakia, Bos-
nia, Croatia, Cyprus, Latvia, Macedonia, Russia, Serbia, Ukraine,
Greece, Republic of Moldova) either provided none or insufﬁcient
data, did not submit updates, or did not give their consent to use
their previous submission.From the questionnaire, the number of megavoltage (MV) units
was calculated as the sum of linear accelerators (including helical
tomotherapy), cobalt-60 and dedicated stereotactic machines.
Simulators for radiotherapy imaging and treatment planning were
classiﬁed as conventional simulators (2D), CT simulators or
simulators with a cone-beam CT option (CBCT).
The number of radiotherapy treatment courses, being primary
treatments, palliative treatments or retreatments, was recorded
in the questionnaire. For the countries where the information
about retreatments was unavailable, the primary treatment ﬁgures
were augmented with 25% [12].
The economic status of the countries was expressed as gross
national income per capita (GNI/n) using the Atlas method [17].
In order to identify relatively homogeneous groups of countries
based on selected characteristics such as the percentage with IMRT
technology, megavoltage machine units per million inhabitants
and GNI/n, we used the k-means clustering via principal compo-
nents analysis using the Hartigan and Wong method [18]. With
this method, multidimensional data can be represented on two
axes and the cluster centroids (vector of mean values of each var-
iable) could be deﬁned. Germany and Italy were excluded from this
part of the analysis since the data related to IMRT capability were
not available. The statistical software R was used to perform this
analysis [19].Results
The validated data on number of radiation treatments, depart-
ments and equipment in the 28 ECO countries form the basis of
the present analysis (Table 1).Equipment
A total of 3024 photon therapy units (2705 MV and 319 kV
machines) and 7 proton facilities were recorded in the 28 coun-
tries. One country did not supply detailed information about MV
unit type; in the remaining 27 countries there were 2192 linear
accelerators, 96 stereotactic machines and 77 cobalt machines
reported. Twelve countries (43%) had at least one cobalt machine
in use. Information about equipment for IMRT and IGRT was avail-
able for 26 countries; a total of 1327 out of 1915 MV units in 26
countries with this information availble were equipped for IMRT
(69%). IGRT equipment was available in 930 of 1915 MV units
(49%). In seven countries (Albania, Belarus, Bulgaria, Hungary,
Ireland, Lithuania, Spain) less than half of the MV machines were
equipped for delivering IMRT, and in 13 countries (Albania, Monte-
negro, Hungary, Bulgaria, Belarus, Spain, Lithuania, Switzerland,
Czech Republic, Ireland, United Kingdom, Slovenia, Portugal) less
than half of the MV units were equipped for IGRT. There was a total
of 96 dedicated stereotactic radiotherapy units in 13 countries; the
remaining 15 countries did not have such equipment (n = 12) or
did not report (n = 3). Simulators for treatment planning were
either 2D kilovoltage (kV; n = 220), CT-simulators (n = 592) or
2D kV units with 3D option (CBCT) (n = 62). Overall, 75% of all
simulators had 3D capability. In three countries (Czech Republic,
Hungary, Lithuania) less than half of the simulators had 3D
capability.Department infrastructure
A total of 872 facilities were recorded in 27 countries, distrib-
uted as 814 departments (93%) and 58 satellites (7%). The highest
number of facilities was in France (n = 176) followed by Italy
(n = 165), Spain (n = 112), and the United Kingdom (n = 77); the
remaining countries had between 1 and 48 centers each. The
Table 1
Data on demographics, average number of treatment machines, simulators and departments in 28 European countries included in the HERO database.













































Albania 2,829,337 4,050 2,195 2010 4 2 0 0 0 2 1 0 0 2 0 0 2 2 2 0
Austria 8,406,187 48,170 21,481 2010 43 42 35 26 1 0 7 0 0 21 8 1 12 14 14 0
Belarus 9,473,000 6,270 2009 30 8 5 4 0 22 18 0 0 20 9 7 4 23 20 3
Belgium 11,047,744 45,840 34,672 2013 91 87 71 57 3 1 8 0 0 29 8 7 14 36 25 11
Bulgaria 7,348,328 6,640 13,794 2012 13 5 2 1 0 8 10 0 0 6 1 1 4 14 14 0
Czech Republic 10,496,088 18,720 32,630 2009 57 43 29 17 4 10 39 1 0 28 18 0 10 48 36 12
Denmark 5,570,572 60,160 17,680 2010 53 53 50 47 0 0 6 0 0 14 0 0 14 9 7 2
Estonia 1,327,439 15,260 2,122 2012 4 4 4 4 0 0 0 0 0 3 1 0 2 2 2 0
Finland 5,388,272 47,740 13,994 2010 43 41 41 41 2 0 0 0 0 17 2 2 13 13 12 1
France 65,343,588 42,690 187,172 2012 449 421 412 238 28 0 11 2 0 165 26 139 176 172 4
Germany 81,797,673 44,230 2010 450 434 16 103
Hungary 9,971,727 12,840 19,951 2011 36 26 6 2 1 9 4 0 0 19 12 0 7 12 12 0
Iceland 319,014 35,260 595 2010 2 2 2 1 0 1 0 0 1 0 1 0 1 1 0
Ireland 4,576,794 38,960 8,373 2009 32 31 10 10 0 1 2 0 0 12 3 0 9 12 12 0
Italy 59,379,449 35,350 2011 340 165 162 3
Lithuania 3,028,115 13,000 6,268 2011 10 10 3 2 0 0 5 0 0 5 4 0 1 5 4 1
Luxembourg 518,347 77,380 1,180 2010 2 2 2 1 0 0 0 0 0 2 1 0 1 1 1 0
Malta 416,268 19,760 535 2014 2 2 1 1 0 0 1 0 0 1 0 0 1 1 1 0
Montenegro 620,644 6,810 1,500 2011 2 2 0 0 0 0 0 0 0 3 1 1 1 1 1 0
The Netherlands 16,693,074 49,660 55,683 2012 132 132 125 125 0 8 0 0 38 8 0 30 29 21 8
Norway 4,953,088 88,500 13,483 2011 41 40 40 40 1 0 6 0 0 22 11 0 11 9 5 4
Poland 38,534,157 12,340 73,500 2010 120 115 109 77 4 1 5 1 0 76 24 16 36 35 35 0
Portugal 10,557,560 21,420 17,957 2010/12 44 41 30 18 3 0 0 0 0 20 3 5 12 17 17 0
Slovenia 2,052,843 23,940 6,023 2012 8 8 5 3 0 0 1 0 0 3 1 0 2 1 1 0
Spain 46,742,697 30,930 98,525 2011 261 220 56 50 36 5 18 0 0 167 35 132 112 112 0
Sweden 9,449,213 53,530 22,678 2012 63 62 51 44 1 0 4 0 0 21 6 0 15 16 15 1
Switzerland 7,912,398 76,350 19,000 2013 59 52 52 12 6 1 11 2 39 13 26 41 37 4
United Kingdom 63,258,918 37,840 2010/11 314 307 186 109 6 1 50 1 0 140 25 21 94 77 73 4
England 53,012,456 n.a. 121,289 2010 268 261 146 86 6 1 46 1 0 117 19 18 80 68 64 4
Scotland 5,295,000 n.a. 2011 25 25 23 16 0 0 1 0 0 13 4 1 8 5 5 0
Wales 3,063,456 n.a. 6,445 2011 13 13 9 7 0 0 3 0 0 7 2 1 4 3 3 0
Northern Ireland 1,810,863 n.a. 4,180 2010 8 8 8 0 0 0 0 0 0 3 0 1 2 1 1 0
No. entries 28 28 24 26 28 27 26 26 25 26 27 26 25 26 26 23 26 27 27 27
Total 488,012,534 973,640 670,991 2705 2192 1327 930 96 77 319 7 0 874 220 62 592 872 814 58
Median 8,159,293 35,305 15,837 2011 43 41 30 15 1 0 5 0 0 20 5 0 11 14 14 0
Min 319,014 4,050 535 2009 2 2 0 0 0 0 0 0 0 1 0 0 0 1 1 0















Calculated indicators for availability of radiotherapy equipment in 28 European countries included in the HERO database.
Countries Indicators
Departments/mil inh MV units/mil inh MV units/dep MV units with IMRT MV units with IGRT Sim/dep Sim/MV unit Sim with 3D Courses/dep Courses/MV
Albania 0.7 1.4 2.0 0% 0% 1.0 0.5 100% 1098 549
Austria 1.7 5.1 3.1 81% 60% 1.5 0.5 62% 1534 500
Belarus 2.1 3.2 1.5 17% 13% 1.0 0.7 55%
Belgium 2.3 8.2 3.6 78% 63% 1.2 0.3 72% 1387 381
Bulgaria 1.9 1.8 0.9 15% 8% 0.4 0.5 83% 985 1061
Czech Republic 3.4 5.4 1.6 51% 30% 0.8 0.5 36% 906 572
Denmark 1.3 9.5 7.6 94% 89% 2.0 0.3 100% 2526 334
Estonia 1.5 3.0 2.0 100% 100% 1.5 0.8 67% 1061 531
Finland 2.2 8.0 3.6 95% 95% 1.4 0.4 88% 1166 325
France 2.6 6.9 2.6 92% 53% 1.0 0.4 84% 1088 417
Germany 5.5
Hungary 1.2 3.6 3.0 17% 6% 1.6 0.5 37% 1663 554
Iceland 3.1 6.3 2.0 100% 50% 1.0 0.5 100% 595 298
Ireland 2.6 7.0 2.7 31% 31% 1.0 0.4 75% 698 262
Italy 2.7 5.7 2.1
Lithuania 1.3 3.3 2.5 30% 20% 1.3 0.5 20% 1567 627
Luxembourg 1.9 3.9 2.0 100% 50% 2.0 1.0 50% 1180 590
Malta 2.4 4.8 2.0 50% 50% 1.0 0.5 100% 535 268
Montenegro 1.6 3.2 2.0 0% 0% 3.0 1.5 67% 1500 750
The Netherlands 1.3 7.9 6.3 95% 95% 1.8 0.3 79% 2652 422
Norway 1.0 8.3 8.2 98% 98% 4.4 0.5 50% 2697 329
Poland 0.9 3.1 3.4 91% 64% 2.2 0.6 68% 2100 613
Portugal 1.6 4.2 2.6 68% 41% 1.2 0.5 85% 1056 408
Slovenia 0.5 3.9 8.0 63% 38% 3.0 0.4 67% 6023 753
Spain 2.4 5.6 2.3 21% 19% 1.5 0.6 79% 880 377
Sweden 1.6 6.7 4.2 81% 70% 1.4 0.3 71% 1512 360
Switzerland 4.7 7.5 1.6 88% 20% 1.1 0.7 67% 514 322
United Kingdom 1.2 5.0 4.3 59% 35% 1.9 0.4 82%
England 1.2 5.1 4.2 54% 32% 1.8 0.4 84% 1895 453
Scotland 0.9 4.7 5.0 92% 64% 2.6 0.5 69%
Wales 1.0 4.2 4.3 69% 54% 2.3 0.5 71% 2148 496
Northern Ireland 0.6 4.4 8.0 100% 0% 3.0 0.4 100% 4180 523
No. entries 27 28 27 26 26 26 26 26 24 24
Total
Median 1.7 5.3 2.6 73% 45% 1.4 0.5 72% 1173 419
Min 0.5 1.4 0.9 0% 0% 0.4 0.3 20% 514 262





































Fig. 1. Histogram showing the average number of radiotherapy treatment machines (MV units) per department in 27 European countries.
C. Grau et al. / Radiotherapy and Oncology 112 (2014) 155–164 159average number of MV units per department ranged from fewer
than two (Belarus, Bulgaria, Czech Republic, Switzerland) to more






























Fig. 2. Histogram showing the average number of radiotherapy treatment mmedian being 2.6 MV units per department (Table 2 and Fig. 1).
There was a median of 1.4 simulators per department (range
0.4–4.4) and 0.5 simulators per MV unit (range 0.3–1.5).5 6 7 8 9 10
achines (MV units) per million inhabitants in 28 European countries.
Fig. 3. Diagram showing the relationship between economic status (GNI per capita) and the average number of radiotherapy treatment machines (MV units) per million
inhabitants in 26 European countries.
Fig. 4. Diagram showing the relationship between economic status (GNI per capita) and the percentage of radiotherapy treatment machines (MV units) capable of delivering
IMRT in 27 European countries.
160 Radiotherapy equipment in EuropeDemographic and economic indicators
The availability of radiotherapy services in relation to key
demographic and economic parameters is presented in Table 2.
The average number of departments per million inhabitants
ranged from 0.5 to 4.7 (median 1.7). This variation was to some
extent reﬂected in a similarly large variation in the average size
of the departments, as shown in Fig. 1.
Fig. 2 shows the average number of MV units per million inhab-
itants; the median number was 5.3. There was a sevenfold varia-tion in this parameter, ranging from very low availability of less
than 2 MV units per million in Albania and Bulgaria to more than
8 MV units per million in Belgium, Denmark and Norway.
There was a signiﬁcant inﬂuence of national economic status on
the availability of radiotherapy services in the 28 European coun-
tries. Fig. 3 shows the correlation between GNI per capita and
the number of MV units per million inhabitants. High-income
countries had more machines per million than countries with
lower GNI per capita. Countries with GNI per capita above USD
Fig. 5. Diagram showing the relationship between economic status (GNI per capita) and the average number of treatment courses per radiotherapy treatment machines (MV
units) in 27 European countries.
Table 3
Correlation between variables included in the k-means clustering via principal
components analysis.
IMRT (%) GNI/n MV units/mil inh
IMRT (%) 1 0.68 0.59
GNI/n 0.68 1 0.76
MV units/mil inh 0.59 0.76 1
Fig. 6. The four clusters found through the k-means clustering via principal
components analysis.
C. Grau et al. / Radiotherapy and Oncology 112 (2014) 155–164 16130,000 in general had more than 4 MV units per million inhabit-
ants, the only exception being Luxembourg (3.9 MV/mil). The eight
countries with GNI per capita below USD 16,000 all had less than
four MV units per million inhabitants.
The economic status also inﬂuenced access to machines with
the ability to deliver highly conformal treatments (IMRT). Fig. 4
shows the relationship between GNI per capita and percentage of
MV units capable of IMRT. As can be seen, more than 75% of
machines could deliver IMRT in countries with GNI/n above USD
40,000, compared to less than 25% in the four lowest income coun-
tries. Poland and Estonia were exceptions, having a high percent-
age of IMRT capability despite a relatively low GNI per capita.
The average number of treatment courses delivered per year per
department varied from fewer than 700 (Switzerland, Ireland, Ice-
land, Malta) to more than 2000 (Poland, Denmark, The Nether-
lands, Norway, Slovenia); the median number was 1173
treatment courses. The median number of treatment courses per
MV unit in 24 countries was 419, with a large variation from fewer
than 300 courses per MV in Ireland, Iceland andMalta to more than
700 in Bulgaria, Montenegro and Slovenia. There was a clear corre-
lation with the socio-economic status, with more treatments deliv-
ered per machine in the countries with the lowest GNI per capita
(Fig. 5).Cluster analysis
Table 3 shows correlations between the three variables (%IMRT,
MV units/mil, GNI/n) used in the clustering analysis. GNI washighly correlated with the percentage of IMRT capability
(r = 0.68) and MV machines per million inhabitants (r = 0.76), how-
ever these last two variables showed a slightly lower correlation
between them (r = 0.59). In the subsequent clustering analysis it
was found that these three variables could be graphically depicted
using two axes which represented 92.7% of the total variability.
Using these two components, we found 4 clusters of countries
(Fig. 6 and Table 4). Cluster 1 deﬁned by Luxembourg, Norway
and Switzerland showed high equipment inventories per million
inhabitants and the highest GNI/n. Countries in cluster 2 (Austria,
Belgium, Denmark, Finland, The Netherlands) had lower GNI/n
but higher equipment inventories per million inhabitants than that
of cluster 1. Cluster 3, formed by France, Iceland, Ireland, Spain and
Table 4
Centroids of the clusters identiﬁed in the k-means clustering via principal components analysis.
Cluster IMRT (%) GNI/n MV units/mil inh
1 Luxembourg, Norway, Switzerland 95.3 80.7 6.6
2 Austria, Belgium, Denmark, Finland, The Netherlands, Sweden 87.3 50.8 7.6
3 France, Iceland, Ireland, Spain, UK 60.6 37.1 6.2
4 Albania, Belarus, Bulgaria, Czech Republic, Estonia, Hungary, Lithuania, Malta, Montenegro, Poland, Portugal, Slovenia 41.8 13.4 3.4
162 Radiotherapy equipment in EuropeUK showed centroid values lower than those of cluster 2. Cluster 4
was formed by former Eastern European countries, Malta, and
Portugal, presented the lowest GNI/n, equipment and IMRT
technology.
Discussion
This is the initial report on the outcome of the ESTRO-HERO
database, based on validated national data, collected in collabora-
tion with the national radiotherapy societies. The main ﬁndings
conﬁrm a large variation between countries for all types of equip-
ment and availability indicators studied.
The ﬁrst parts of the HERO project build on the experience of
the QUARTS-project, the ﬁrst real attempt to arrive at estimates
for the appropriate level of radiotherapy infrastructure and stafﬁng
in Europe [12,20]. The two main equipment indicators from
QUARTS were MV units per million inhabitants and number of
treatments per MV unit. Ofﬁcial guidelines for the number of linear
accelerators and personnel were available in about 40% of the
countries in the QUARTS analysis. For accelerators, the analysis of
guidelines came to a recommendation of an average of 5.5 MV
units/million in the high, 3.5 MV units/million in the medium
and 2.0 MV units/million in the low resource countries [20]. These
numbers have not changed signiﬁcantly over the last decade, as
illustrated in the update of guidelines survey performed as part
of the HERO project [16]. In the second part of the QUARTS analysis
[12], the best available evidence on radiotherapy indications in 23
main cancer types was combined with epidemiological data from
all 25 EU countries at that time and with published benchmarks
for accelerator throughput. A large variation in crude cancer inci-
dence observed within the analyzed EU countries translated into
a similarly large variation in the estimated number of required lin-
ear accelerators per million inhabitants (between 4.0 and 8.1 linear
accelerators/million inhabitants), hovering around a European
average of 5.9. In the current HERO data set, the actual number
was 5.3 MV units/million, meaning that the overall European aver-
age is now close to the QUARTS guideline standard for high income
countries, albeit with a signiﬁcant sevenfold difference from the
highest to the lowest coverage. The lowest income countries all
have less than 4 MV units per million inhabitants, and the highest
income countries have close to 10 MV units per million. This socio-
economic disparity was also highlighted in the recent IAEA DIRAC
study [13]. Despite some discussion about potential problems with
the DIRAC data previously addressed [21,22], the two studies thus
reach the same overall conclusions about the heterogeneity in
radiotherapy equipment availability between European countries.
Whether the actual need is still 5.9 MV units/million will be
reﬁned in the ongoing HERO project by calculating the needs based
on actual cancer incidence in the individual countries and using
evidence-based indications for radiotherapy.
Although the high correlations observed between GNI and MV
units per million inhabitants and the percentage with IMRT could
suggest the conclusion that economic resources available at
country level are the main determinants of the radiotherapyequipment, the cluster analysis showed that the situation is not so
straight forward. The countries included in the cluster with the
highest GNI (Luxemburg, Norway, and Switzerland) do not have
the highest number of MV per million, although they have the most
technological updated equipment. From this perspective, it could be
suggested that health policy decisions at country level matters.
The number of patients treated per MV unit is often used as a
measure of machine productivity. From the guidelines, QUARTS
estimated a European benchmark of 450 patients per machine
per year, with an estimate of 400–450 patients per year accounting
for increasing complexity. The recent HERO update of available
guidelines showed no major change in this recommendation over
the last decade [16]. In the current analysis of actually available
equipment, the benchmark is reached, as the median number of
treatment courses was 419 per MV unit. As shown in Fig. 5 there
was a striking variation in machine throughput, which seemed to
be related to the socio-economic status of the country, with high
values in low income countries. In many of these low income
countries, the equipment is being utilized for extended hours. In
e.g. Slovenia, where the average throughput is over 700 patients
per linear accelerator, all machines are used in two shifts per
day. It can be seen from Table 2 that these countries also have
the least advanced technology available, i.e. fewer linear
accelerators capable of IMRT and IGRT, and relatively more cobalt
units. The throughput is also dependent upon other factors,
including referral base, complexity of treatment and the age of
the equipment. Increasing use of high quality advanced conformal
treatments and daily imaging will in many situations be more
time-consuming and thus put a limit to how many treatments a
machine can deliver. This is further discussed in the HERO stafﬁng
paper [15].
The type of radiotherapy equipment available in the European
countries differed signiﬁcantly. In total, 69% of all MV units were
equipped for IMRT and 49% for IGRT, with much higher rates in
high income countries. A number of Eastern European countries
still have cobalt machines, which are not able to deliver modern
conformal treatments. This skewed distribution was also noted in
the DIRAC study [13].
The size of radiotherapy departments is an indicator of the
organizational infrastructure. In the Nordic countries, Poland, The
Netherlands and Slovenia, radiotherapy services are centralized
in departments treating on average more than 1600 patients per
year. Such large departments enable subspecialization of the staff.
In the Dutch model, each radiation oncologist has 2–3 areas of
expertise; to cover all tumor sites it is necessary to have at least
eight specialists, which again require 1600–2000 patients per year
to be efﬁcient [23]. In most other European countries, however,
facilities are small with only one or two machines. An average of
fewer than 1,000 courses per year per department, as seen in eight
countries (Malta, Switzerland, Iceland, Ireland, Spain, Czech Repub-
lic and Bulgaria), may indicate a fragmentation of radiotherapy
services, which potentially inﬂuence treatment quality and might
have negative effect on productivity. The major cost components
of radiotherapy are buildings, equipment and staff. Due to the
C. Grau et al. / Radiotherapy and Oncology 112 (2014) 155–164 163economics of scaling, the average cost per patient decreases with
increasing department size and optimal utilization of resources.
Earlier studies concluded that the costs per patient substantially
decrease when a department is treating more than 1000 patients
annually [24] or 1000–1200 annually [25]. Similar calculations
have been done for Canada [26], ﬁnding a threshold about 1600
patients annually.
This HERO study has several limitations. We used national
averages of institutional data, collected by individuals in the
national societies over several years. This will inevitably intro-
duce bias and variation in the data. Although we have tried to
validate the data by repeated updates and comparison to other
sources, and exclusion of the least reliable datasets, there will
be some uncertainty in the presented data. This uncertainty spe-
ciﬁcally applies to data on complexity of the equipment (IMRT,
IGRT, SRS), which are also sensitive to the time of data collection,
since the ﬁeld is quickly evolving. The survey also collected
equipment capability only and did not collect data to understand
if the equipment was actually being used to its full capability.
This is important as equipment can be operational without the
new technologies actually being implemented, e.g. due to limited
workforce availability and constraints related to skills or
resources. Finally, the interpretation in the various countries of
speciﬁc entities such as ‘dedicated stereotactic equipment’ and
‘intra-operative linacs’ may have been different in different coun-
tries. Since these units are only a very small fraction of the total
machines, such variations will have little impact on the overall
conclusions.
Collecting and validating the data has been a huge task for
many of the representatives from the national societies. It is our
hope that the experience obtained and the collegial network
established through this project will be valuable not only for
future updates of the HERO database but also forming the basis
for more qualiﬁed discussions within the national societies[21].
The next step in the HERO framework is to benchmark the data
to the equipment needs in the individual countries, based on can-
cer incidence and stage mix and performed in cooperation with
the Collaboration for Cancer Outcomes, Research and Evaluation
(CCORE) in Australia. The data will also be used in developing
the HERO costing model for European countries, in order to pro-
vide budgetary estimates of the radiotherapy optimization pro-
cess in various jurisdictions.
In conclusion, the results of this survey document a signiﬁcant
heterogeneity in the access to modern radiotherapy equipment in
Europe. Although the European average number of MV machines
per million inhabitants and per department is now better in line
with QUARTS recommendations from 2005, there is still a signiﬁ-
cant heterogeneity in the access to radiotherapy equipment in Eur-
ope. While high income countries especially in Northern–Western
Europe are well-served with radiotherapy resources, other coun-
tries are facing important shortages of both equipment in general
and especially machines capable of delivering high precision con-
formal treatments (IMRT, IGRT).Conﬂict of interest
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